Beta-2 adrenoceptor agonists for treating connective tissue...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/135 (2006.01) A61P 19/04 (2006.01) A61P 37/00 (2006.01) A61P 37/06 (2006.01)

Patent

CA 2604758

The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.

La présente invention concerne des médicaments efficaces et sûrs destinés au traitement des maladies du tissu conjonctif cutané, en particulier pour ce qui est du traitement de formes cutanées de l'érythème lupus. Ces médicaments comprennent comme principe thérapeutiquement actif un agoniste d'adrénocepteur beta2 . Cette invention concerne aussi des compositions dermatologiques sans propriétés de sensibilisation cutanée et qui contient un agoniste d'adrénocepteur beta2 énantiomériquement pur ou à énantiomères R enrichis.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Beta-2 adrenoceptor agonists for treating connective tissue... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Beta-2 adrenoceptor agonists for treating connective tissue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta-2 adrenoceptor agonists for treating connective tissue... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1422633

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.